<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00610272</url>
  </required_header>
  <id_info>
    <org_study_id>E33028</org_study_id>
    <nct_id>NCT00610272</nct_id>
  </id_info>
  <brief_title>Optimization of Radiotherapy in Treatment of Painful Bone Metastasis</brief_title>
  <acronym>bone mets</acronym>
  <official_title>Investigation of Optimal Radiotherapy Regimen and Type of Irradiation in Treatment of Painful Bone Metastasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>International Atomic Energy Agency</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>International Atomic Energy Agency</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bone metastasis is one of the most frequent end complications of the cancer. Radiation
      therapy is the mainstay of treatment in this disease. Single fraction radiotherapy in both
      single and multiple bone metastasis is widely used, but optimization of the single dose
      fractionation is needed. Two different regimens of radiotherapy dose fractionation will be
      investigated in both single and multiple bone metastasis and endpoints will include pain
      relief as well as toxicity and quality of life.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PROTOCOL SCHEMA

      Group A Treatment of single site of painful bone metastasis:

      Arm 1: 4 Gy single fraction; mandate first retreatment if moderate or severe pain persists or
      recurs (as measured by categorical pain scale or VAS greater than 50 mm), &gt;4 weeks after
      initial RT) retreat with 8 Gy single fraction; second retreatment is optional if moderate or
      severe pain recurs (as measured by categorical pain scale or VAS greater than 50 mm), retreat
      with 8 Gy after &gt; 4 weeks

      Arm 2: 8 Gy single fraction, mandate first retreatment if moderate or severe pain persists or
      recurs (as measured by categorical pain scale or VAS greater than 50 mm), &gt;4 weeks after
      initial RT) retreat with 8 Gy single fraction; second retreatment is optional if moderate or
      severe pain recurs (as measured by categorical pain scale or VAS greater than 50 mm), retreat
      with 8 Gy after &gt; 4 weeks

      Group B Treatment of multiple bone metastasis: lower hemibody radiotherapy (LHBI):

      Arm 3: 8 Gy in a single fraction; retreatments &gt; 4 weeks, using local RT fields to sites of
      residual or recurrent, moderate or severe pain with a single fraction of 8 Gy) ; second
      reirradiation with 8 Gy using local RT fields optional (at discretion of PI);

      Arm 4: 12 Gy in 4 fractions of 3 Gy in 2 consecutive days interfraction interval of a minimum
      of 6 hrs; retreatments &gt; 4 weeks using local RT fields to sites of residual or recurrent,
      moderate or severe pain with a single fraction of 8 Gy); second reirradiation with 8 Gy using
      local RT fields optional (at discretion of PI) ;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Relief (response rate) at 4 weeks</measure>
    <time_frame>Up to 52 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Onset and Duration of Pain Relief in Responders</measure>
    <time_frame>Up to 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>Up to 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>Up to 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of Pathological Fractures and Spinal Cord Compression</measure>
    <time_frame>Up to 52 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">650</enrollment>
  <condition>Pain</condition>
  <condition>Bone Metastasis</condition>
  <arm_group>
    <arm_group_label>Single Site Radiation 4Gy Fraction</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 Gy single fraction; mandate first retreatment if moderate or severe pain persists or recurs (as measured by categorical pain scale or VAS greater than 50 mm), &gt;4 weeks after initial RT) retreat with 8 Gy single fraction; second retreatment is optional if moderate or severe pain recurs (as measured by categorical pain scale or VAS greater than 50 mm), retreat with 8 Gy after &gt; 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single Site Radiation 8Gy Fraction</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>8 Gy single fraction, mandate first retreatment if moderate or severe pain persists or recurs (as measured by categorical pain scale or VAS greater than 50 mm), &gt;4 weeks after initial RT) retreat with 8 Gy single fraction; second retreatment is optional if moderate or severe pain recurs (as measured by categorical pain scale or VAS greater than 50 mm), retreat with 8 Gy after &gt; 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple Sites Radiation 8Gy Fraction</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>8 Gy in a single fraction; retreatments &gt; 4 weeks, using local RT fields to sites of residual or recurrent, moderate or severe pain with a single fraction of 8 Gy) ; second reirradiation with 8 Gy using local RT fields optional (at discretion of PI);</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple Sites Radiation 12Gy Fraction</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 Gy in 4 fractions of 3 Gy in 2 consecutive days interfraction interval of a minimum of 6 hrs; retreatments &gt; 4 weeks using local RT fields to sites of residual or recurrent, moderate or severe pain with a single fraction of 8 Gy); second reirradiation with 8 Gy using local RT fields optional (at discretion of PI) ;</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>4 Gy single fraction; mandate first retreatment if moderate or severe pain persists or recurs (as measured by categorical pain scale or VAS greater than 50 mm), &gt;4 weeks after initial RT) retreat with 8 Gy single fraction; second retreatment is optional if moderate or severe pain recurs (as measured by categorical pain scale or VAS greater than 50 mm), retreat with 8 Gy after &gt; 4 weeks</description>
    <arm_group_label>Single Site Radiation 4Gy Fraction</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>8 Gy single fraction, mandate first retreatment if moderate or severe pain persists or recurs (as measured by categorical pain scale or VAS greater than 50 mm), &gt;4 weeks after initial RT) retreat with 8 Gy single fraction; second retreatment is optional if moderate or severe pain recurs (as measured by categorical pain scale or VAS greater than 50 mm), retreat with 8 Gy after &gt; 4 weeks</description>
    <arm_group_label>Single Site Radiation 8Gy Fraction</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>8 Gy in a single fraction; retreatments &gt; 4 weeks, using local RT fields to sites of residual or recurrent, moderate or severe pain with a single fraction of 8 Gy) ; second reirradiation with 8 Gy using local RT fields optional (at discretion of PI);</description>
    <arm_group_label>Multiple Sites Radiation 8Gy Fraction</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>12 Gy in 4 fractions of 3 Gy in 2 consecutive days interfraction interval of a minimum of 6 hrs; retreatments &gt; 4 weeks using local RT fields to sites of residual or recurrent, moderate or severe pain with a single fraction of 8 Gy); second reirradiation with 8 Gy using local RT fields optional (at discretion of PI) ;</description>
    <arm_group_label>Multiple Sites Radiation 12Gy Fraction</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  histological diagnosis of malignancy associated with radiological evidence of painful
             bone metastasis

          -  If patients with two sites of pain requiring separate treatment are to be entered, the
             same randomized treatment option will be used for both sites, but response at each
             site will be scored and analyzed separately.

          -  age &gt; 18 years

          -  anticipated remaining life of at least 12 weeks (3 months)

          -  informed consent

        Exclusion Criteria:

          -  Primary histology myeloma

          -  Sites of previous RT or previous radioisotope treatment

          -  conditions or circumstances, which may interfere with treatment or follow-up

          -  complicated bone metastasis (pathological fractures, metastatic spinal cord
             compression)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elena Fidarova, MD</last_name>
    <role>Study Chair</role>
    <affiliation>International Atomic Energy Agency</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Pierre et Marie Curie, Centre hospitalier universitaire Mustapha (CHU)</name>
      <address>
        <city>Alger</city>
        <zip>16016</zip>
        <country>Algeria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Irmandade de Santa Casa de Misericordia de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <zip>90020-090</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Misr Oncology Center (MOC)</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tata Memorial Hospital</name>
      <address>
        <city>Mumbai</city>
        <zip>Maharashtra 400 012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Oncology, University of Vilinius</name>
      <address>
        <city>Vilnius</city>
        <zip>08660</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Radiotherapy and Oncology</name>
      <address>
        <city>Skopje</city>
        <zip>1000</zip>
        <country>Macedonia, The Former Yugoslav Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Cancerología (INCAN)</name>
      <address>
        <city>Ciudad de Mexico</city>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Oncology and Radiology</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic Universidad de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Son Dureta</name>
      <address>
        <city>Palma de Mallorca</city>
        <zip>07014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut national de cancer Salah Azaiz</name>
      <address>
        <city>Tunis</city>
        <zip>Bab Saadoun 1006</zip>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Vernon Cancer Centre</name>
      <address>
        <city>Northwood</city>
        <zip>HA6 2 RN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Algeria</country>
    <country>Brazil</country>
    <country>Egypt</country>
    <country>India</country>
    <country>Lithuania</country>
    <country>Macedonia, The Former Yugoslav Republic of</country>
    <country>Mexico</country>
    <country>Serbia</country>
    <country>Spain</country>
    <country>Tunisia</country>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Salazar OM, DaMotta NW, Bridgman SM, Cardiges NM, Slawson RG. Fractionated half-body irradiation for pain palliation in widely metastatic cancers: comparison with single dose. Int J Radiat Oncol Biol Phys. 1996 Aug 1;36(1):49-60.</citation>
    <PMID>8823258</PMID>
  </reference>
  <reference>
    <citation>Salazar OM, Sandhu T, da Motta NW, Escutia MA, Lanzós-Gonzales E, Mouelle-Sone A, Moscol A, Zaharia M, Zaman S. Fractionated half-body irradiation (HBI) for the rapid palliation of widespread, symptomatic, metastatic bone disease: a randomized Phase III trial of the International Atomic Energy Agency (IAEA). Int J Radiat Oncol Biol Phys. 2001 Jul 1;50(3):765-75.</citation>
    <PMID>11395246</PMID>
  </reference>
  <reference>
    <citation>Mithal NP, Needham PR, Hoskin PJ. Retreatment with radiotherapy for painful bone metastases. Int J Radiat Oncol Biol Phys. 1994 Jul 30;29(5):1011-4.</citation>
    <PMID>7521863</PMID>
  </reference>
  <reference>
    <citation>Hoskin PJ, Price P, Easton D, Regan J, Austin D, Palmer S, Yarnold JR. A prospective randomised trial of 4 Gy or 8 Gy single doses in the treatment of metastatic bone pain. Radiother Oncol. 1992 Feb;23(2):74-8.</citation>
    <PMID>1372126</PMID>
  </reference>
  <reference>
    <citation>Wu JS, Wong R, Johnston M, Bezjak A, Whelan T; Cancer Care Ontario Practice Guidelines Initiative Supportive Care Group. Meta-analysis of dose-fractionation radiotherapy trials for the palliation of painful bone metastases. Int J Radiat Oncol Biol Phys. 2003 Mar 1;55(3):594-605. Review.</citation>
    <PMID>12573746</PMID>
  </reference>
  <reference>
    <citation>Gaze MN, Kelly CG, Kerr GR, Cull A, Cowie VJ, Gregor A, Howard GC, Rodger A. Pain relief and quality of life following radiotherapy for bone metastases: a randomised trial of two fractionation schedules. Radiother Oncol. 1997 Nov;45(2):109-16. Review.</citation>
    <PMID>9423999</PMID>
  </reference>
  <reference>
    <citation>Arcangeli G, Micheli A, Arcangeli G, Giannarelli D, La Pasta O, Tollis A, Vitullo A, Ghera S, Benassi M. The responsiveness of bone metastases to radiotherapy: the effect of site, histology and radiation dose on pain relief. Radiother Oncol. 1989 Feb;14(2):95-101.</citation>
    <PMID>2469105</PMID>
  </reference>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 25, 2008</study_first_submitted>
  <study_first_submitted_qc>February 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2008</study_first_posted>
  <last_update_submitted>August 6, 2013</last_update_submitted>
  <last_update_submitted_qc>August 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 7, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>single bone metastasis</keyword>
  <keyword>multiple bone metastasis</keyword>
  <keyword>pain relief</keyword>
  <keyword>radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Bone Neoplasms</mesh_term>
    <mesh_term>Bone Marrow Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

